Saturday, July 11, 2026

pharma · Leiomyosarcoma · Friedreich Ataxia

PTC Therapeutics Iberia

PTC Therapeutics Iberia clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Madrid, ES HQ
1998 Founded
5 Employees
EMA registrant Type
Company details
Status
Public
HQ
Madrid, ES
Founded
1998
Employees
5
Programs
2
Drugs
0
Patents
0
Intelligence · Clinical Programs

PTC Therapeutics Iberia projects

2 ClinicalTrials.gov programs sponsored by PTC Therapeutics Iberia.

PTC Therapeutics Iberia has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Unesbulin

    PTC Therapeutics International Limited

    Leiomyosarcoma

    phase 3 small molecule terminated

    1 trial
  2. Vatiquinone

    PTC Therapeutics International Limited

    Friedreich Ataxia

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does PTC Therapeutics Iberia have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.